Overview

A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

Status:
RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

This is a single-arm, open-label study to evaluate the efficacy and safety of VRD-based regimen combined with BCMA CAR-T in transplant-ineligible patients with primary plasma cell leukemia

Phase:

PHASE2

Details

Lead Sponsor:

Institute of Hematology & Blood Diseases Hospital, China